Pharmacokinetics of a florfenicol-tylosin combination after intravenous and intramuscular administration to beagle dogs.
A pharmacokinetic study of a commercial florfenicol-tylosin (2:1) combination product was conducted in six beagle dogs after intravenous (IV) and intramuscular (IM) administration at doses of 10 mg/kg (florfenicol) and 5 mg/kg (tylosin). Serum drug concentrations were determined by a validated high performance liquid chromatography (HPLC) using UV detection. A rapid and nearly complete absorption of both drugs with a mean IM bioavailability of 103.9% (florfenicol) and 92.6% (tylosin), prolonged elimination half-life, and high tissue penetration with steady state volume of distribution of 2.63 l/kg (florfenicol) and 1.98 l/kg (tylosin) were observed. Additional studies, including pharmacodynamic and toxicological evaluation are required before recommendations can be made regarding the clinical application of the product in dogs.
Gyeongbuk Veterinary Service Laboratory, Daegu 702–210, Republic of Korea.
Eun-Young
EY
Kim
Elias
E
Gebru
Joong-Su
JS
Lee
Jong-Choon
JC
Kim
Seung-Chun
SC
Park
D000818:Animals; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000493:pharmacokinetics; D019540:Area Under Curve; D001682:Biological Availability; D002851:Chromatography, High Pressure Liquid; D018592:Cross-Over Studies; D004285:Dogs / Q000097:blood* / Q000378:metabolism; D004338:Drug Combinations; D006207:Half-Life; D007273:Injections, Intramuscular; D007275:Injections, Intravenous; D008297:Male; D013839:Thiamphenicol / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000493:pharmacokinetics; D015645:Tylosin / Q000008:administration & dosage* / Q000493:pharmacokinetics*
D000900:Anti-Bacterial Agents; D004338:Drug Combinations; C035534:florfenicol; D013839:Thiamphenicol; D015645:Tylosin